我们可以使用HER2DX来调节HER2阳性早期乳腺癌的治疗强度吗？

IF 0.2 Q4 OBSTETRICS & GYNECOLOGY

Revista de Senologia y Patologia Mamaria Pub Date : 2025-01-21 DOI:10.1016/j.senol.2024.100659

Beatriz Alonso De Castro , Cristina Reboredo Rendo , Fernanda Mosele , Eva Pérez López , Lourdes Calvo Martínez , Silvia Antolín Novoa

{"title":"我们可以使用HER2DX来调节HER2阳性早期乳腺癌的治疗强度吗？","authors":"Beatriz Alonso De Castro , Cristina Reboredo Rendo , Fernanda Mosele , Eva Pérez López , Lourdes Calvo Martínez , Silvia Antolín Novoa","doi":"10.1016/j.senol.2024.100659","DOIUrl":null,"url":null,"abstract":"<div><div>Clinical HER2 positive (cHER2+) breast cancer (BC) is an heterogenous disease, which represents a major challenge in the design of personalized therapeutic strategies. In recent years, a great development against HER2 targeted therapies took place, but not all patients benefit from the same regimens. In this context, it is essential to develop genomic analysis, with clinicopathological and molecular biomarkers, as HER2DX, in order to improve response, safety, and patient's quality of life. This review aims to comprehensively summarize the current evidence regarding the development, validation, and application of HER2DX score in clinical practice. Genomic development and clinical application in the identification of different cHER2+ BC populations are discussed, along as future changing strategies for escalation and de-escalation treatments.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100659"},"PeriodicalIF":0.2000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Can we use HER2DX to modulate treatment intensity in HER2 positive early breast cancer?\",\"authors\":\"Beatriz Alonso De Castro , Cristina Reboredo Rendo , Fernanda Mosele , Eva Pérez López , Lourdes Calvo Martínez , Silvia Antolín Novoa\",\"doi\":\"10.1016/j.senol.2024.100659\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Clinical HER2 positive (cHER2+) breast cancer (BC) is an heterogenous disease, which represents a major challenge in the design of personalized therapeutic strategies. In recent years, a great development against HER2 targeted therapies took place, but not all patients benefit from the same regimens. In this context, it is essential to develop genomic analysis, with clinicopathological and molecular biomarkers, as HER2DX, in order to improve response, safety, and patient's quality of life. This review aims to comprehensively summarize the current evidence regarding the development, validation, and application of HER2DX score in clinical practice. Genomic development and clinical application in the identification of different cHER2+ BC populations are discussed, along as future changing strategies for escalation and de-escalation treatments.</div></div>\",\"PeriodicalId\":38058,\"journal\":{\"name\":\"Revista de Senologia y Patologia Mamaria\",\"volume\":\"38 3\",\"pages\":\"Article 100659\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2025-01-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista de Senologia y Patologia Mamaria\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0214158224000872\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de Senologia y Patologia Mamaria","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0214158224000872","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

临床HER2阳性（cHER2 +）乳腺癌（BC）是一种异质性疾病，这代表了个性化治疗策略设计的主要挑战。近年来，针对HER2靶向治疗取得了重大进展，但并非所有患者都能从相同的治疗方案中受益。在这种情况下，有必要发展基因组分析，与临床病理和分子生物标志物，如HER2DX，以提高反应，安全性和患者的生活质量。本文旨在全面总结目前关于HER2DX评分在临床实践中的发展、验证和应用的证据。本文讨论了基因组学的发展和在鉴定不同cHER2 + BC人群中的临床应用，以及未来升级和降级治疗的变化策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Can we use HER2DX to modulate treatment intensity in HER2 positive early breast cancer?

Clinical HER2 positive (cHER2 +) breast cancer (BC) is an heterogenous disease, which represents a major challenge in the design of personalized therapeutic strategies. In recent years, a great development against HER2 targeted therapies took place, but not all patients benefit from the same regimens. In this context, it is essential to develop genomic analysis, with clinicopathological and molecular biomarkers, as HER2DX, in order to improve response, safety, and patient's quality of life. This review aims to comprehensively summarize the current evidence regarding the development, validation, and application of HER2DX score in clinical practice. Genomic development and clinical application in the identification of different cHER2 + BC populations are discussed, along as future changing strategies for escalation and de-escalation treatments.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Revista de Senologia y Patologia Mamaria Medicine-Obstetrics and Gynecology

CiteScore

0.30

自引率

0.00%

发文量

审稿时长

63 days